1. International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2013-2018, Adult and Pediatric Units, Device-associated Module
- Author
-
Umesh Gupta, Lul Raka, Debkishore Gupta, Anucha Apisarnthanarak, Rayo Morfin-Otero, Michael M. Petrov, Victor D. Rosenthal, Antonio Cerero-Gudiño, Vaidotas Gurskis, Naheed Elahi, Sona Hlinkova, Dolatsinh Zala, Edwin Giovanny Chapeta-Parada, Volkan Baytaş, Julio Cesar Vimercati, Estuardo Salgado-Yepez, Humberto Guanche-Garcell, Tanja Anguseva, María Guadalupe Miranda-Novales, Nayide Barahona-Guzmán, Chin Seng Gan, Rajesh Chawla, Nadia Tayyab, Amani El-Kholy, Eduardo Alexandrino Servolo Medeiros, Subhash Todi, Bat-Erdene Ider, Asma Bouziri, Hail M. Al-Abdely, Blanca Estela Hernandez-Chena, Kavita Raja, Namita Upadhyay, Hala Agha, Suna Secil Ozturk-Deniz, Victoria D. Villanueva, Ertugrul Guclu, Nurettin Erben, Amina Barkat, Dincer Yildizdas, Nguyen Viet Hung, Asu Özgültekin, Nirav Pandya, Hala Joudi, Farid Zand, Safa A Aziz AlKhawaja, Souad Belkebir, Jaroslaw Janc, Tahsine Mahfouz, Ata Nevzat Yalcin, Vladislav A Belskii, Nefise Oztoprak-Cuvalci, Recep Tekin, Yatin Mehta, Florin George Horhat, Kushlani Jayatilleke, Nepomuceno Mejia, Aruna Poojary, Saroj Kumar Pattnaik, Katherine Gomez-Nieto, Vesna Mioljevic, Sheila Nainan Myatra, Wiesława Duszyńska, Pravin K Nair, Emrah Gün, Guadalupe Aguirre-Avalos, Gustavo Jorge Chaparro, Mona Moheyeldin Abdelhalim, Le Thi Thu Nguyet, Abeer Aly Omar, Achilleas Gikas, Mariana Mrazova, Majeda A Al-Ruzzieh, Wan Rahiza Wan Mat, Souha S. Kanj, Mohit Kharbanda, Anjeela Koirala, Dale Fisher, Sanghamitra Mishra, Anju Mathew, and Daisy Aguilar-De-Morós
- Subjects
Imipenem ,antibiotic resistance ,healthcare associated infection ,Epidemiology ,Staphylococcus ,vancomycin ,Ceftazidime ,intensive care unit ,Nosocomial infection ,0302 clinical medicine ,device infection ,Klebsiella ,amikacin ,colistin ,Prospective Studies ,030212 general & internal medicine ,ceftazidime ,Child ,ventilator associated event ,catheter infection ,Cross Infection ,0303 health sciences ,adult ,Health Policy ,Pneumonia, Ventilator-Associated ,Bacterial Infections ,cohort analysis ,infection control ,Device-associated infection ,Ciprofloxacin ,Intensive Care Units ,Infectious Diseases ,Amikacin ,Pseudomonas aeruginosa ,Urinary Tract Infections ,Limited resources countries ,Vancomycin ,disease surveillance ,hospital infection ,pediatric intensive care unit ,prospective study ,medicine.drug ,Staphylococcus aureus ,medicine.medical_specialty ,Health care-associated infection ,Bacterial resistance ,Article ,03 medical and health sciences ,length of stay ,ciprofloxacin ,Internal medicine ,Intensive care ,medicine ,Humans ,human ,nonhuman ,treatment duration ,030306 microbiology ,business.industry ,medical device complication ,bacterial infection ,Public Health, Environmental and Occupational Health ,oxacillin ,Nosocomial infection control ,major clinical study ,Catheter-Related Infections ,Colistin ,ventilator associated pneumonia ,urinary tract infection ,business ,Enterococcus ,imipenem - Abstract
Background We report the results of INICC surveillance study from 2013 to 2018, in 664 intensive care units (ICUs) in 133 cities, of 45 countries, from Latin-America, Europe, Africa, Eastern-Mediterranean, Southeast-Asia, and Western-Pacific. Methods Prospective data from patients hospitalized in ICUs were collected through INICC Surveillance Online System. CDC-NHSN definitions for device-associated healthcare-associated infection (DA-HAI) were applied. Results We collected data from 428,847 patients, for an aggregate of 2,815,402 bed-days, 1,468,216 central line (CL)-days, 1,053,330 mechanical ventilator (MV)-days, 1,740,776 urinary catheter (UC)-days. We found 7,785 CL-associated bloodstream infections (CLAB), 12,085 ventilator-associated events (VAE), and 5,509 UC-associated urinary tract infections (CAUTI). Pooled DA-HAI rates were 5.91% and 9.01 DA-HAIs/1,000 bed-days. Pooled CLAB rate was 5.30/1,000 CL-days; VAE rate was 11.47/1,000 MV-days, and CAUTI rate was 3.16/1,000 UC-days. P aeruginosa was non-susceptible (NS) to imipenem in 52.72% of cases; to colistin in 10.38%; to ceftazidime in 50%; to ciprofloxacin in 40.28%; and to amikacin in 34.05%. Klebsiella spp was NS to imipenem in 49.16%; to ceftazidime in 78.01%; to ciprofloxacin in 66.26%; and to amikacin in 42.45%. coagulase-negative Staphylococci and S aureus were NS to oxacillin in 91.44% and 56.03%, respectively. Enterococcus spp was NS to vancomycin in 42.31% of the cases. Conclusions DA-HAI rates and bacterial resistance are high and continuous efforts are needed to reduce them.
- Published
- 2021